[96a5a0]: / output / allTrials / identified / NCT00127920_identified.json

Download this file

415 lines (415 with data), 17.6 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
{
"info": {
"nct_id": "NCT00127920",
"official_title": "A Phase II, Open-Label, Non-Randomized, Multi-Center Pilot Study of Intravenous Taxol, Carboplatin, Bevacizumab Given Every 21 Days in Patients With Newly Diagnosed Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",
"inclusion_criteria": "* Subjects with a histologic or cytologic diagnosis of stage III/IV ovarian cancer, fallopian tube epithelial cancer, or peritoneal cancer who have not received prior chemotherapy or radiotherapy.\n* Subjects must have the appropriate surgery for their gynecologic cancer. However, subjects may be treated in a neoadjuvant manner, with surgery being performed after chemotherapy cycles 1, 2, or 3.\n* If neoadjuvant therapy is not administered, subjects must receive their first dose no more than six weeks postoperatively.\n* Subjects must have adequate bone marrow, renal and hepatic function as defined by WBC > 3,000 cells/cu ml., platelets > 100,000/cu.ml., calculated creatinine clearance > 50 ccs/min., bilirubin < 1.5 mg/dl, and SGOT < three times normal.\n* Karnofsky performance status > 50%.\n* Subjects who have signed an institutional review board (IRB) approved informed consent form.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Subjects with epithelial ovarian cancer of low malignancy potential.\n* Subjects with septicemia, severe infection, or acute hepatitis.\n* Subjects with severe gastrointestinal bleeding.\n* Subjects with a history of congestive heart failure, angina, or a history of myocardial infarction within the past six months.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Subjects with a histologic or cytologic diagnosis of stage III/IV ovarian cancer, fallopian tube epithelial cancer, or peritoneal cancer who have not received prior chemotherapy or radiotherapy.",
"criterions": [
{
"exact_snippets": "histologic or cytologic diagnosis",
"criterion": "diagnosis method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologic",
"cytologic"
]
}
]
},
{
"exact_snippets": "stage III/IV ovarian cancer",
"criterion": "ovarian cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"III",
"IV"
]
}
]
},
{
"exact_snippets": "fallopian tube epithelial cancer",
"criterion": "fallopian tube epithelial cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "peritoneal cancer",
"criterion": "peritoneal cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "have not received prior chemotherapy or radiotherapy",
"criterion": "prior treatment",
"requirements": [
{
"requirement_type": "treatment history",
"expected_value": false
}
]
}
]
},
{
"line": "* Subjects must have the appropriate surgery for their gynecologic cancer. However, subjects may be treated in a neoadjuvant manner, with surgery being performed after chemotherapy cycles 1, 2, or 3.",
"criterions": [
{
"exact_snippets": "appropriate surgery for their gynecologic cancer",
"criterion": "surgery for gynecologic cancer",
"requirements": [
{
"requirement_type": "appropriateness",
"expected_value": true
}
]
},
{
"exact_snippets": "treated in a neoadjuvant manner",
"criterion": "neoadjuvant treatment",
"requirements": [
{
"requirement_type": "treatment type",
"expected_value": "neoadjuvant"
}
]
}
]
},
{
"line": "* If neoadjuvant therapy is not administered, subjects must receive their first dose no more than six weeks postoperatively.",
"criterions": [
{
"exact_snippets": "neoadjuvant therapy is not administered",
"criterion": "neoadjuvant therapy",
"requirements": [
{
"requirement_type": "administration",
"expected_value": false
}
]
},
{
"exact_snippets": "receive their first dose no more than six weeks postoperatively",
"criterion": "first dose timing",
"requirements": [
{
"requirement_type": "timing",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "weeks postoperatively"
}
}
]
}
]
},
{
"line": "* Karnofsky performance status > 50%.",
"criterions": [
{
"exact_snippets": "Karnofsky performance status > 50%",
"criterion": "Karnofsky performance status",
"requirements": [
{
"requirement_type": "performance status",
"expected_value": {
"operator": ">",
"value": 50,
"unit": "%"
}
}
]
}
]
},
{
"line": "* Subjects who have signed an institutional review board (IRB) approved informed consent form.",
"criterions": [
{
"exact_snippets": "signed an institutional review board (IRB) approved informed consent form",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "approval",
"expected_value": "IRB approved"
},
{
"requirement_type": "status",
"expected_value": "signed"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Subjects with epithelial ovarian cancer of low malignancy potential.",
"criterions": [
{
"exact_snippets": "epithelial ovarian cancer",
"criterion": "epithelial ovarian cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "low malignancy potential",
"criterion": "malignancy potential",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "low"
}
]
}
]
},
{
"line": "* Subjects with septicemia, severe infection, or acute hepatitis.",
"criterions": [
{
"exact_snippets": "Subjects with septicemia",
"criterion": "septicemia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "severe infection",
"criterion": "severe infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "acute hepatitis",
"criterion": "acute hepatitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Subjects with severe gastrointestinal bleeding.",
"criterions": [
{
"exact_snippets": "severe gastrointestinal bleeding",
"criterion": "gastrointestinal bleeding",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
}
]
},
{
"line": "* Subjects with a history of congestive heart failure, angina, or a history of myocardial infarction within the past six months.",
"criterions": [
{
"exact_snippets": "history of congestive heart failure",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "angina",
"criterion": "angina",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "history of myocardial infarction within the past six months",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": "within the past six months"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"line": "* Subjects must have adequate bone marrow, renal and hepatic function as defined by WBC > 3,000 cells/cu ml., platelets > 100,000/cu.ml., calculated creatinine clearance > 50 ccs/min., bilirubin < 1.5 mg/dl, and SGOT < three times normal.",
"criterions": [
{
"exact_snippets": "adequate bone marrow ... WBC > 3,000 cells/cu ml.",
"criterion": "bone marrow function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
},
{
"requirement_type": "WBC count",
"expected_value": {
"operator": ">",
"value": 3000,
"unit": "cells/cu ml"
}
}
]
},
{
"exact_snippets": "adequate ... renal function ... calculated creatinine clearance > 50 ccs/min.",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
},
{
"requirement_type": "creatinine clearance",
"expected_value": {
"operator": ">",
"value": 50,
"unit": "ccs/min"
}
}
]
},
{
"exact_snippets": "adequate ... hepatic function ... bilirubin < 1.5 mg/dl, and SGOT < three times normal.",
"criterion": "hepatic function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
},
{
"requirement_type": "bilirubin level",
"expected_value": {
"operator": "<",
"value": 1.5,
"unit": "mg/dl"
}
},
{
"requirement_type": "SGOT level",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "times normal"
}
}
]
},
{
"exact_snippets": "platelets > 100,000/cu.ml.",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">",
"value": 100000,
"unit": "cu.ml"
}
}
]
}
]
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}